🇺🇸 FDA
Pipeline program

Intraparenchymal rAAV1 - (mi)RNA HTT

VY-HTT01-1

Phase 1 gene_therapy terminated

Quick answer

Intraparenchymal rAAV1 - (mi)RNA HTT for Huntington Disease is a Phase 1 program (gene_therapy) at Voyager Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Voyager Therapeutics
Indication
Huntington Disease
Phase
Phase 1
Modality
gene_therapy
Status
terminated

Clinical trials